SPOTLIGHT -
EP. 1: Introduction: Treating ALL in Adult Patients
EP. 2: Novel Therapies for Patients Ph-Negative ALL
EP. 3: Emerging Strategies in the Treatment of ALL
EP. 4: Surrogate Endpoints for New Drug Discovery in ALL
EP. 5: Efficacy and Future Role of Ibrutinib in CLL and MCL
EP. 6: Combining and Sequencing New Agents in CLL
EP. 7: Bcl-2 Inhibition With ABT-199 in CLL, Lymphomas
EP. 8: PI3K Inhibition in Hematologic Malignancies
EP. 9: Brentuximab Vedotin in Diffuse Large B-cell Lymphoma
EP. 10: Combination Therapy in Large Cell Lymphomas
EP. 11: Changing Therapeutic Landscape in ALL, CLL, and NHL
Up-Front Osimertinib Provides Comparable OS, Improved Brain PFS Vs Sequential Gefitinib/Osimertinib in EGFR+ NSCLC
Dr Nasioudis on the Use of NGS to Identify the Molecular Profile of Endometroid Ovarian Cancer
Dr Buckingham on the Use of Patient-reported Outcomes to Predict Frailty in Patients With Ovarian Cancer
Dr Slomovitz on the Investigation of Letrozole Plus Ribociclib in Low-Grade Serous Ovarian Carcinoma
